NCT06324266View on ClinicalTrials.gov

Study on the Efficacy and Safety of Low-dose CTX as Maintenance Therapy for MM Unsuitable for Transplantation

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

April 16, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Newly Diagnosed Multiple Myeloma
Interventions
DRUG

Cyclophosphamide

Standard risk group MM patients who achieve VGPR or above after initial induction and consolidation therapy and are not suitable transplantation, are maintained with Cyclophosphamide monotherapy for 2 years.

DRUG

Lenalidomide

Standard risk group MM patients who achieve VGPR or above after initial induction and consolidation therapy and are not suitable transplantation, are maintained with Lenalidomide monotherapy for 2 years.

Trial Locations (1)

Unknown

RECRUITING

Jinling Hospital, Nanjing

All Listed Sponsors
lead

Jinling Hospital, China

OTHER